Get all premium features to the best stock analysis tool

Finranks

Company

About us

Contact us

[email protected]

Follow us

Instagram
Telegram
LinkedIn

All rights reserved.

Privacy Policy Terms of Conditions

Home
Markets
Screener
News
About

Home

NTRA

N

Natera, Inc. (NTRA)

NMS – Real Time Price. Currency in USD

182.65

-13.50 (-6.88%)

At close: Mar 27, 2026, 4:00 PM EDT

182.83

+0.18 (0.10%)

After-hours: Mar 27, 2026, 7:39 PM EDT

Summary
News
Chart
Financial
Dividends
Forecast
Ownership
Profile

Natera Looks Compelling As Oncology Testing Momentum Keeps Building

Natera Looks Compelling As Oncology Testing Momentum Keeps Building

NTRA's oncology franchise, led by Signatera MRD testing, is the main bull case at this point. As long as they keep building on their testing volumes, I believe this should support a long runway in cancer monitoring and recurrence detection. NTRA's 2025 also included new product launches and added Medicare coverage, advanced early cancer detection, and broadened its molecular diagnostics portfolio.

NTRA Debuts Zenith Genomics Next-Gen Sequencing Test for Rare Diseases

NTRA Debuts Zenith Genomics Next-Gen Sequencing Test for Rare Diseases

Natera launches Zenith genomics whole-genome sequencing assay with MyOme to boost rare disease detection and expand diagnostics reach across the United States.

Two Publications Highlight Clinical Utility of Signatera™ in Anal and Rectal Cancers

Two Publications Highlight Clinical Utility of Signatera™ in Anal and Rectal Cancers

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced two peer-reviewed publications highlighting the clinical utility of Signatera, its personalized, tumor-informed circulating tumor DNA (ctDNA) assay, in anal squamous cell carcinoma (ASCC) and locally advanced rectal cancer (LARC). ASCC: publication in Nature Communications A recently published study evaluated 84 patients with ASCC to assess whether serial Signate.

Invesco Main Street Mid Cap Fund Q4 2025 Portfolio Activity

Invesco Main Street Mid Cap Fund Q4 2025 Portfolio Activity

We maintain our valuation discipline and our focus on companies with competitive advantages and skilled management teams that we believe are executing better than their peers. We initiated a position in Tractor Supply after recent share weakness created a compelling entry point, in our view. Tyler Technologies was sold because the software provider's revenue growth has decelerated, which reduced our conviction in its upside potential.

Natera Announces Commercial Launch of Zenith™ Genomics for Rare Disease Diagnosis

Natera Announces Commercial Launch of Zenith™ Genomics for Rare Disease Diagnosis

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the commercial launch of Zenith genomics, its next-generation whole genome sequencing assay designed to significantly improve the detection of rare diseases. Natera is presenting on Zenith's unique platform and performance at the 2026 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting, taking place this week in Baltimore, Ma.

MyOme Debuts Zenith™ Portfolio with Natera and Launches Long-Read Methylation Analysis at ACMG 2026

MyOme Debuts Zenith™ Portfolio with Natera and Launches Long-Read Methylation Analysis at ACMG 2026

MENLO PARK, Calif., March 12, 2026 /PRNewswire/ -- MyOme, a leader in clinical whole-genome analysis, announced an advancement in rare disease diagnostics at the American College of Medical Genetics and Genomics (ACMG) Annual Meeting.

Natera, Inc. (NTRA) Presents at Leerink Global Healthcare Conference 2026 Transcript

Natera, Inc. (NTRA) Presents at Leerink Global Healthcare Conference 2026 Transcript

Natera, Inc. (NTRA) Presents at Leerink Global Healthcare Conference 2026 Transcript

Videos

No Data

There is no data to display

Press releases

Two Publications Highlight Clinical Utility of Signatera™ in Anal and Rectal Cancers

Two Publications Highlight Clinical Utility of Signatera™ in Anal and Rectal Cancers

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced two peer-reviewed publications highlighting the clinical utility of Signatera, its personalized, tumor-informed circulating tumor DNA (ctDNA) assay, in anal squamous cell carcinoma (ASCC) and locally advanced rectal cancer (LARC). ASCC: publication in Nature Communications A recently published study evaluated 84 patients with ASCC to assess whether serial Signate.

MyOme Debuts Zenith™ Portfolio with Natera and Launches Long-Read Methylation Analysis at ACMG 2026

MyOme Debuts Zenith™ Portfolio with Natera and Launches Long-Read Methylation Analysis at ACMG 2026

MENLO PARK, Calif., March 12, 2026 /PRNewswire/ -- MyOme, a leader in clinical whole-genome analysis, announced an advancement in rare disease diagnostics at the American College of Medical Genetics and Genomics (ACMG) Annual Meeting.

Natera Announces Commercial Launch of Zenith™ Genomics for Rare Disease Diagnosis

Natera Announces Commercial Launch of Zenith™ Genomics for Rare Disease Diagnosis

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the commercial launch of Zenith genomics, its next-generation whole genome sequencing assay designed to significantly improve the detection of rare diseases. Natera is presenting on Zenith's unique platform and performance at the 2026 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting, taking place this week in Baltimore, Ma.

Signatera™ MRD Data at ASCO GU Highlights Potential Utility Across GU Cancers, Including for Bladder Preservation

Signatera™ MRD Data at ASCO GU Highlights Potential Utility Across GU Cancers, Including for Bladder Preservation

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced it will present new data in genitourinary malignancies at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), taking place February 26-28, 2026. Across four oral presentations in muscle-invasive bladder cancer (MIBC), these data reinforce Signatera's role in identifying patients who benefit from adjuvant immunotherapy, supporting.